# Sumit Gupta

Source: https://onco.cc/people/sumit-gupta/  
OnCo record `sumit-gupta` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led COG AALL1731, which showed adding blinatumomab to chemotherapy improves survival for children with standard-risk leukaemia.

## Summary

Sumit Gupta was study chair of Children's Oncology Group AALL1731, the randomised trial showing that adding the CD19 bispecific blinatumomab to chemotherapy dramatically improves disease-free survival in children with newly diagnosed standard-risk B-cell acute lymphoblastic leukaemia, the largest advance in front-line childhood ALL in decades. He also studies disparities and outcomes in paediatric cancer at SickKids.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: paediatric; all; immunotherapy
- Role: Staff Oncologist and Senior Scientist, The Hospital for Sick Children (SickKids), Toronto
- Specialisms: Paediatric acute lymphoblastic leukaemia; Immunotherapy; Health outcomes research; Cooperative-group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D%20blinatumomab%20AALL1731

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD3](https://onco.cc/targets/cd3/)
- drugs: [Blinatumomab](https://onco.cc/drugs/blinatumomab/)
- institutions: [The Hospital for Sick Children (SickKids)](https://onco.cc/institutions/sickkids/)
- trials: [COG AALL1731](https://onco.cc/trials/aall1731/)
- key papers: [Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL](https://onco.cc/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/)
- journals: [Cancer](https://onco.cc/journals/cancer-wiley/)

---
JSON: https://onco.cc/api/v1/entities/sumit-gupta.json